Thiotepa is a chemotherapy medication used in high-dose therapy for treating medulloblastoma, a type of brain tumor. It works by interfering with cancer cell DNA, helping to stop tumor growth.

Radiotherapy is a treatment that uses high-energy radiation beams to target and destroy cancer cells. The trial compares two different approaches to radiation therapy:
– Conventional radiotherapy, which delivers radiation once per day
– Hyperfractionated-accelerated radiotherapy (HART), which delivers radiation multiple times per day in smaller doses

The trial also includes maintenance chemotherapy, which is long-term treatment given after the main treatment to help prevent the cancer from returning. Two different maintenance chemotherapy approaches are being compared in this study.

Medulloblastoma – A rare type of brain tumor that starts in the lower back part of the brain called the cerebellum. It begins when brain cells have changes in their DNA, causing cells to grow and divide uncontrollably. The disease can occur in different subtypes, including sonic hedgehog (SHH) and Groups 3 and 4 variants. Medulloblastoma tends to spread through the cerebrospinal fluid that surrounds and protects the brain and spinal cord. The condition can affect both children and adults, though it’s more commonly found in children.